Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 10 X users

Readers on

mendeley: 81 Mendeley

So far, Altmetric has seen 12 X posts from 10 X users, with an upper bound of 25,694 followers.

RT @jitcancer: New #JITC article: Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients wi…

RT @ZakhariaYousef: Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced me…

RT @jitcancer: New #JITC article: Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients wi…

New #JITC article: Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma @ZakhariaYousef https://t.co/jUJjRHptqU https://t.co/LO39M3K817

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.